Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nutraceutical Files For Appellate Court Rehearing Of Ephedra Ban Suit

This article was originally published in The Tan Sheet

Executive Summary

The appellate court decision that upheld FDA's 2004 ephedra ban overextends the agency's authority and blurs the line between food and drug regulation, attorneys for marketer Nutraceutical say in a request for rehearing

You may also be interested in...



Nutraceutical Renews Ephedra Case In Utah Court; FDA To Respond By Jan. 18

FDA did not provide advance notice and opportunity for public comment when it "created a new adulteration standard" in its 2004 final rule banning ephedra alkaloids in dietary supplements, Nutraceutical argues in a motion renewing its case against FDA

Nutraceutical Renews Ephedra Case In Utah Court; FDA To Respond By Jan. 18

FDA did not provide advance notice and opportunity for public comment when it "created a new adulteration standard" in its 2004 final rule banning ephedra alkaloids in dietary supplements, Nutraceutical argues in a motion renewing its case against FDA

Nutraceutical Renews Ephedra Case In Utah Court; FDA To Respond By Jan. 18

FDA did not provide advance notice and opportunity for public comment when it "created a new adulteration standard" in its 2004 final rule banning ephedra alkaloids in dietary supplements, Nutraceutical argues in a motion renewing its case against FDA

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel